NewsRamp Psychedelics Podcast

NewsRamp Psychedelics Podcast

Explore the emerging world of psychedelics with the 'NewsRamp Psychedelics Podcast.' This podcast delivers the latest news and insights from NewsRamp.com, focusing on research developments, therapeutic applications, and regulatory changes in the psychedelics field. Stay informed on the groundbreaking advancements in this evolving industry.

Episodes

Psyence Biomedical Chief to Speak at Psychedelic Science 2025 Conference

June 18, 2025 • 2 mins
Mary-Elizabeth Gifford, Chief of Global Impact at Psyence Biomedical Ltd., will be a featured speaker at Psychedelic Science 2025, discussing business ethics in the realm of psychedelic research. Psyence Biomedical is a Nasdaq-listed biopharma company focusing on nature-derived psilocybin medicine for FDA approval.
Mark as Played

Advancements in Cybin Inc.'s Phase 3 Psychedelic Therapeutics Program

June 13, 2025 • 2 mins
Cybin Inc. provided an update on its Phase 3 Psychedelic Therapeutics Program, highlighting progress in the clinical pipeline, with the lead candidate CYB003 advancing into Phase 3 development. CEO Doug Drysdale expressed confidence in the company's IP portfolio and clinical strategy, noting positive shifts in regulatory sentiment as a key factor in expediting the review process. Cybin is focused on creating safe and effective psyc...
Mark as Played

Innovations in Psychedelic Therapeutics: Updates from Cybin Inc., NRx Pharmaceuticals Inc., and Silo Pharma Inc.

June 12, 2025 • 4 mins
Cybin Inc. CEO Doug Drysdale will be speaking at the H.C. Wainwright Neuro Perspectives Conference and the Psychedelic Science 2025 Conference, highlighting the company's focus on developing psychedelic-based therapeutics for mental health conditions. Meanwhile, NRx Pharmaceuticals Inc. has filed an application for a preservative-free ketamine formulation to address the shortage of ketamine in the U.S., and Silo Pharma Inc. has rec...
Mark as Played

NRx Pharmaceuticals Announces Acquisition of Kadima Neuropsychiatry Institute and Plans to Launch $100 Million Psychiatry Clinic Network

June 5, 2025 • 3 mins
NRx Pharmaceuticals, a clinical-stage biopharmaceutical company, has acquired Kadima Neuropsychiatry Institute to establish a network of interventional psychiatry clinics. The subsidiary, HOPE Therapeutics, aims to open up to 30 clinics by 2025, with a projected $100 million run rate. NRx has also filed an ANDA for its preservative-free IV ketamine formulation, NRX-100, targeting the U.S. ketamine market and seeking to broaden its ...
Mark as Played

Empower Your Audience with Rythmia: Join the Affiliate Program Today!

June 3, 2025 • 2 mins
Rythmia Life Advancement Center's new affiliate program targets wellness influencers, healers, and marketers to promote its life-changing experiences in Costa Rica. Offering competitive commissions and second-tier referral earnings, partners can share in Rythmia's mission of healing and transformation while earning income. Visit Rythmia's website for more details on this unique opportunity.
Mark as Played

Cybin Inc. Secures U.S. Patent for CYB004 Anxiety Treatment Candidate

June 3, 2025 • 1 min
Cybin Inc. has obtained a U.S. patent for its CYB004 anxiety treatment candidate, extending exclusivity through 2040. CEO Doug Drysdale emphasized the potential of CYB004 to provide rapid-acting, short-duration treatment with a patient-friendly delivery system. The compound is in Phase 2 trials, projected to conclude by mid-2025, solidifying Cybin's position as a frontrunner in innovative mental health therapies.
Mark as Played

Biotech Updates: Incannex Healthcare, Lophora, and NRx Pharmaceuticals

May 28, 2025 • 3 mins
Stonegate Capital Partners provided an update on Incannex Healthcare Inc., reporting reduced expenses and strengthened financial position. Lophora initiated a Phase 1 trial for LPH-5 targeting CNS disorders, aiming to provide therapeutic benefits without hallucinogenic effects. NRx Pharmaceuticals announced a $10.3 million financing to expand its HOPE Clinic Network and advance FDA drug approval for neuroplastic therapies.
Mark as Played

Advancement in PTSD Treatment: Silo Pharma's Nasal Spray Device Study

May 21, 2025 • 1 min
Silo Pharma Inc. is making strides in their PTSD treatment with a drug-device study on a microchip-enabled nasal spray system for SPC-15 in partnership with Resyca BV. The study aims to gather final device data for an FDA application, with CEO Eric Weisblum emphasizing the device's potential to bypass the blood-brain barrier for faster and safer therapeutic delivery. Additionally, the company is progressing with other SPC-15 studie...
Mark as Played

Advancements in Psychedelic Therapeutics: Cybin Inc., Republican Lawmakers, and Silo Pharma Inc.

May 20, 2025 • 3 mins
Cybin Inc. is making progress in Phase 3 and Phase 2 trials for psychedelic therapeutics targeting mental health conditions, supported by FDA approval. Republican lawmakers like Rep. Morgan Luttrell are advocating for therapeutic use of psychedelics for veterans, while Silo Pharma Inc. recently closed a public offering to fund their research in psychiatric disorders and CNS diseases.
Mark as Played

Biopharmaceutical Companies Silo Pharma Inc. and NRx Pharmaceuticals, Inc. Make Advancements in Drug Development and Financials

May 16, 2025 • 3 mins
Silo Pharma Inc. has priced a public offering of common stock and warrants to raise $2 million, supporting its work on therapeutic treatments for psychiatric disorders and chronic pain. Meanwhile, NRx Pharmaceuticals, Inc. reported a Q1 net loss decrease, progress on ketamine and bipolar depression treatments, and funding for its psychiatry clinic subsidiary.
Mark as Played

Advancements in Psychedelic-Based Therapeutics by Cybin Inc., Silo Pharma Inc., and NRx Pharmaceuticals Inc.

May 15, 2025 • 5 mins
Cybin Inc. partners with Thermo Fisher Scientific for manufacturing of CYB003, a deuterated psilocin treatment for major depressive disorder. Silo Pharma Inc. collaborates with Veloxity Labs for bioanalysis supporting a PTSD treatment, while NRx Pharmaceuticals reports financial results post the acquisition of Kadima Neuropsychiatry Institute. All three companies focus on developing psychedelic-based therapeutics for mental health ...
Mark as Played

Advancing Research on THC-Infused Beverages and Protecting Access to 7-OHM: Industry Initiatives in Focus

May 7, 2025 • 2 mins
Love Yer Brain, part of Iconic Tonics, is collaborating with MoreBetter to study the impact of THC-infused beverages, aiming to provide insights into consumer preferences for alcohol alternatives. Meanwhile, the 7-HOPE Alliance has been established to protect legal access to 7-hydroxymitragynine (7-OHM) and promote responsible usage through science and advocacy efforts.
Mark as Played

Innovations in Psychedelic Therapeutics and Pain Management at the Milken Conference

May 5, 2025 • 4 mins
Cybin Inc. CEO Doug Drysdale will discuss drug development innovation and next-generation mental health treatments at the Milken Institute Global Conference. Meanwhile, Silo Pharma Inc. has reported positive preclinical data for its SP-26 Ketamine Implant for fibromyalgia and filed a patent application for SPC-14 targeting cognitive and neuropsychiatric symptoms in Alzheimer’s disease, showcasing advancements in pain management and...
Mark as Played

Promising Results from Beckley Psytech's ELE-101 Phase 1 Trial for Major Depressive Disorder

June 26, 2024 • 2 mins
In this episode, Atai Life Sciences co-founder and co-CEO Florian Brand discusses the promising initial results from Beckley Psytech's phase 1 trial of ELE-101 for major depressive disorder. ELE-101, an IV formulation of psilocin, aims to shorten treatment duration to two hours, with good tolerance and safety shown in phase one trials. The phase 2 trial is underway with data expected later this year. Brand also highlights the poten...
Mark as Played

Exploring Ibogaine: A Breakthrough in Addiction Therapy with Deborah Mash, PhD

June 25, 2024 • 2 mins
Join neuroscientist Deborah Mash, PhD, on 'Psychedelic Breakthrough Addiction Therapy' as she explores cutting-edge research on breakthrough addiction therapies, focusing on psychedelic medicines like Ibogaine. Dr. Mash, with thirty years of experience in addiction neuroscience, offers insight into groundbreaking therapies with the potential to transform lives. Tune in to CannabisRadio.com to learn more about the renaissance of psy...
Mark as Played

Exploring the Future of Psychedelic Therapy with Tryptamine Therapeutics Inc.

June 5, 2024 • 2 mins
Join host Jonathan Jackson as he speaks with Tryptamine Therapeutics Inc. CEO Jason Carroll about the company's recent debut on the Australian Securities Exchange. Tryptamine Therapeutics is focused on developing an intravenous-infused psilocin formulation for psychedelic therapy, with core programs like TRP-8803 and TRP-8802 showing promising results in trials for conditions like fibromyalgia, IBS, and BED. Backed by a qualified B...
Mark as Played

Popular Podcasts

    Cold Case Files: Miami

    Cold Case Files: Miami

    Joyce Sapp, 76; Bryan Herrera, 16; and Laurance Webb, 32—three Miami residents whose lives were stolen in brutal, unsolved homicides.  Cold Case Files: Miami follows award‑winning radio host and City of Miami Police reserve officer  Enrique Santos as he partners with the department’s Cold Case Homicide Unit, determined family members, and the advocates who spend their lives fighting for justice for the victims who can no longer fight for themselves.

    24/7 News: The Latest

    24/7 News: The Latest

    The latest news in 4 minutes updated every hour, every day.

    Crime Junkie

    Crime Junkie

    Does hearing about a true crime case always leave you scouring the internet for the truth behind the story? Dive into your next mystery with Crime Junkie. Every Monday, join your host Ashley Flowers as she unravels all the details of infamous and underreported true crime cases with her best friend Brit Prawat. From cold cases to missing persons and heroes in our community who seek justice, Crime Junkie is your destination for theories and stories you won’t hear anywhere else. Whether you're a seasoned true crime enthusiast or new to the genre, you'll find yourself on the edge of your seat awaiting a new episode every Monday. If you can never get enough true crime... Congratulations, you’ve found your people. Follow to join a community of Crime Junkies! Crime Junkie is presented by audiochuck Media Company.

    The Clay Travis and Buck Sexton Show

    The Clay Travis and Buck Sexton Show

    The Clay Travis and Buck Sexton Show. Clay Travis and Buck Sexton tackle the biggest stories in news, politics and current events with intelligence and humor. From the border crisis, to the madness of cancel culture and far-left missteps, Clay and Buck guide listeners through the latest headlines and hot topics with fun and entertaining conversations and opinions.

    The Breakfast Club

    The Breakfast Club

    The World's Most Dangerous Morning Show, The Breakfast Club, With DJ Envy And Charlamagne Tha God!

Advertise With Us
Music, radio and podcasts, all free. Listen online or download the iHeart App.

Connect

Explore

iHeart

Live Radio

Podcasts

Artist Radio

Exclusives

News

Features

Events

Contests

Photos

Information

About

Advertise

Blog

Brand Guidelines

Contest Guidelines

Subscription Offers

Jobs

Get the App

Automotive

Home

Mobile

Wearables

© 2025 iHeartMedia, Inc.